Glioma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The glioma market reached a value of USD 1.04 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 1.59 Billion by 2035, exhibiting a growth rate (CAGR) of 3.95% during 2025-2035.

The glioma market has been comprehensively analyzed in IMARC's new report titled "Glioma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". Glioma is a type of brain tumor that primarily originates in the glial cells of the brain or spinal cord. These cells are essential for the body as they provide structural integrity, nourishment, and protection to the neurons in the central nervous system. The disease can vary in its degree of malignancy or aggressiveness. Some of the common symptoms may include persistent headaches, seizures, changes in vision, difficulty speaking or understanding language, weakness or paralysis in certain body parts, cognitive and memory problems, personality changes, and balance and coordination issues. Numerous other indications may arise depending on the specific area of the brain affected by the tumor. The diagnosis of glioma involves a combination of medical history assessment, physical examination, and various diagnostic tests. The process typically begins with a thorough medical history and neurological exam to assess symptoms and neurological function. The healthcare provider may further perform several imaging procedures, such as positron emission tomography scans, X-rays, magnetic resonance imaging, etc., to visualize the brain and detect the presence of tumors.

The rising prevalence of genetic conditions that lead to an accumulation of mutated DNA in glial stem or progenitor cells, causing them to grow uncontrollably, is primarily driving the glioma market. In addition to this, the increasing incidences of exposure to ionizing radiation that can trigger the activation of downstream signaling molecules, resulting in accelerated cell division and tumor formation, are also creating a positive outlook for the market. Moreover, the widespread adoption of immunotherapy with immune checkpoint inhibitors, since they stimulate the body's defense system to recognize and attack unhealthy cells, is further augmenting the market growth. Apart from this, the inflating application of stereotactic radiosurgery, a non-invasive treatment procedure that delivers a highly focused radiation dose into the brain to significantly prolong survival in patients, is also acting as another significant growth-inducing factor. Additionally, the escalating demand for tumor-treating field therapy owing to its numerous advantages, such as being more tolerable and convenient with minimum systemic side effects as compared to other conventional regimens, is expected to drive the glioma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the glioma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for glioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the glioma market in any manner.

Recent Developments:

• In March 2025, Laminar Pharma announced optimistic results from its ongoing clinical trial evaluating LAM561 for the treatment of newly diagnosed glioblastoma.
• In February 2025, Chimerix disclosed that the U.S. FDA had accepted its New Drug Application (NDA) seeking accelerated approval for dordaviprone as a treatment for patients with recurrent H3 K27M-mutant diffuse glioma. The application had been granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 18, 2025.
• In April 2024, Day One Biopharmaceuticals announced that the U.S. FDA had approved OJEMDA (tovorafenib) for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
• In March 2023, Novartis stated that the U.S. FDA had granted approval for Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of pediatric patients 1 year of age and older with low-grade glioma with a BRAF V600E mutation who require systemic therapy. The FDA also approved liquid formulations of Tafinlar and Mekinist, marking the first time a BRAF/MEK inhibitor has been developed in a formulation suitable for patients as young as one year of age.

Key Highlights:

• Gliomas are the most frequent primary intracranial tumor, accounting for 81% of all malignant brain tumors.
• It is the 17th most frequent cancer type worldwide, with more than 250,000 new cases identified each year.
• Men are 1.3 times more likely than women to develop glioma, with the exception of diffuse midline gliomas, which are more common in women.
• Northern Europe, the U.S. white population, and Israel have reported high rates of primary malignant brain tumors.
• Grade 2 gliomas, such as diffuse astrocytomas, have a five-year survival rate of approximately 40-50%.
• Grade 4 gliomas (such as glioblastoma) are the most aggressive, with a five-year survival rate of approximately 5-10%.

Drugs:

GLIADEL Wafer (polifeprosan 20 with carmustine implant) is recommended for newly diagnosed high-grade malignant glioma patients in addition to surgery and radiation. This therapy comes in a single dose box with 8 individually pouched wafers. Each wafer has 7.7 mg of carmustine and is packaged in two aluminum foil laminate pouches.

LAM561 is a novel oral drug for glioblastoma that works by modifying the composition of cancer cell membranes. This modification disrupts signaling pathways crucial for tumor growth, effectively halting cancer cell proliferation and potentially leading to cell death. LAM561 is a synthetic derivative of oleic acid and is able to cross the blood-brain barrier, allowing it to target tumor cells within the brain.

ONC201, a first‑in‑class imipridone by Chimerix, targets gliomas by antagonizing dopamine D2/D3 receptors and activating the mitochondrial protease ClpP. This triggers the integrated stress response (via ATF4/CHOP), inhibits Akt/ERK signaling, upregulates TRAIL/DR5, disrupts mitochondrial respiration, and induces tumor cell apoptosis.

AB-218 is a novel, powerful, and highly selective mutant IDH-1 inhibitor with high blood-brain barrier permeability. It has shown promising safety and efficacy signs in a Phase 1 trial of glioma patients.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the glioma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the glioma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current glioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the glioma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the glioma across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the glioma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of glioma across the seven major markets?
• What is the number of incident cases (2019-2035) of glioma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of glioma by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of glioma by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with glioma across the seven major markets?
• What is the size of the glioma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend glioma of?
• What will be the growth rate of patients across the seven major markets?

Glioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for glioma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the glioma market?
• What are the key regulatory events related to the glioma market?
• What is the structure of clinical trial landscape by status related to the glioma market?
• What is the structure of clinical trial landscape by phase related to the glioma market?
• What is the structure of clinical trial landscape by route of administration related to the glioma market?